HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
Status:
Completed
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
This pilot phase I trial studies the side effects and best dose of histone deacetylase (HDAC)
inhibitor AR-42 (AR-42) when given together with pomalidomide in treating patients with
multiple myeloma that has returned after a period of improvement. HDAC inhibitor AR-42 may
work to stop cancer growth by blocking an enzyme needed for cell growth. Pomalidomide is a
drug used in chemotherapy that works to stop the growth of cancer cells by causing them to
die. Giving HDAC inhibitor AR-42 together with pomalidomide may cause patients to respond
better to treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Ohio State University Comprehensive Cancer Center Yvonne Efebera